peacekat,
It's time for this board to get excited, IMO.
In my my previous post, I mentioned how surprised I was that the board wasn't excited yesterday following the publication of the RO(x2) paper. Unfortunately, the malaise of the shareholder base has been caused by the constant fear-mongering we have been enduring. Here's another piece of that report that got my juices flowing.
"While CCR5 is known for its role in facilitating human immunodeficiency virus (HIV) infection of CD4+ T cells, it has a wide range of roles in normal and pathophysiological processes. In addition to HIV, CCR5 is a critical host receptor for Dengue virus (5) and Staphylococcus aureus (6) infection. Furthermore, high expression of CCR5 is associated with cancer progression and tumorigenesis (7–9), development of insulin resistance via adipose tissue macrophage recruitment (10), and suppression of cortical plasticity, learning, and memory (11–13). Moreover, individuals homozygous for the naturally occurring CCR5 mutation, CCR5Δ32, lack cell surface expression of CCR5 receptors, which has protective effects against HIV infection (14, 15), asthma (16, 17), severe SARS-CoV-2 symptoms (18), and development of rheumatoid arthritis (19), and is associated with improved hepatitis B virus infection recovery rates (20) and lower incidence of cardiovascular disease (21, 22). However, CCR5 is critical for viral clearance after infection by West Nile (23), Japanese encephalitis (24), and influenza A viruses (25, 26) because of its role in trafficking immune cells to sites of infection. Exemplifying the complexity of CCR5, the lack of CCR5 receptors protected against parasitic Toxoplasma gondii infection (27) while the presence of CCR5 was essential for disease control after infection (28, 29). Because of the myriad roles played by CCR5, the ability to target CCR5 with therapeutic agents will have a diverse range of applications."
One more I just fully comprehended from the following paragraph of the paper...
"Additionally, the paucity of CCR5+ CD4+ T cells present in natural hosts of simian immunodeficiency virus (SIV) during infancy protects against mother-to-offspring transmission during breastfeeding by viremic mothers (36). Thus, the level of CCR5 occupied by a CCR5-targeting drug is a critical predictor of its therapeutic efficacy."
Good Luck to you,
chazzle
It's time for this board to get excited, IMO.
In my my previous post, I mentioned how surprised I was that the board wasn't excited yesterday following the publication of the RO(x2) paper. Unfortunately, the malaise of the shareholder base has been caused by the constant fear-mongering we have been enduring. Here's another piece of that report that got my juices flowing.
"While CCR5 is known for its role in facilitating human immunodeficiency virus (HIV) infection of CD4+ T cells, it has a wide range of roles in normal and pathophysiological processes. In addition to HIV, CCR5 is a critical host receptor for Dengue virus (5) and Staphylococcus aureus (6) infection. Furthermore, high expression of CCR5 is associated with cancer progression and tumorigenesis (7–9), development of insulin resistance via adipose tissue macrophage recruitment (10), and suppression of cortical plasticity, learning, and memory (11–13). Moreover, individuals homozygous for the naturally occurring CCR5 mutation, CCR5Δ32, lack cell surface expression of CCR5 receptors, which has protective effects against HIV infection (14, 15), asthma (16, 17), severe SARS-CoV-2 symptoms (18), and development of rheumatoid arthritis (19), and is associated with improved hepatitis B virus infection recovery rates (20) and lower incidence of cardiovascular disease (21, 22). However, CCR5 is critical for viral clearance after infection by West Nile (23), Japanese encephalitis (24), and influenza A viruses (25, 26) because of its role in trafficking immune cells to sites of infection. Exemplifying the complexity of CCR5, the lack of CCR5 receptors protected against parasitic Toxoplasma gondii infection (27) while the presence of CCR5 was essential for disease control after infection (28, 29). Because of the myriad roles played by CCR5, the ability to target CCR5 with therapeutic agents will have a diverse range of applications."
One more I just fully comprehended from the following paragraph of the paper...
"Additionally, the paucity of CCR5+ CD4+ T cells present in natural hosts of simian immunodeficiency virus (SIV) during infancy protects against mother-to-offspring transmission during breastfeeding by viremic mothers (36). Thus, the level of CCR5 occupied by a CCR5-targeting drug is a critical predictor of its therapeutic efficacy."
Good Luck to you,
chazzle
13
